The Patent Finder

Liver Disease

Lipocine Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 62/701,309, filed Jul 20, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,097,207Liver Disease
In force
 · Medium confidence
Lipocine, Inc.In force
Medium confidence
US 12,150,945Liver Disease
In force
 · Medium confidence
Lipocine Inc.In force
Medium confidence
US 11,931,367Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy
In force
 · High confidence
Lipocine, Inc.In force
High confidence
US 12,156,881Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy
In force
 · High confidence
Lipocine Inc.In force
High confidence
US 12,318,396Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy
In force
 · Low confidence
Lipocine, Inc.In force
Low confidence
Application 16/554,444Liver Disease
Pending
Not granted
Lipocine Inc.PendingNot granted
Application 17/001,813Liver Disease
Abandoned
Abandoned Oct 21, 2025
Lipocine, Inc.AbandonedAbandoned Oct 21, 2025
Application 17/001,855Liver Disease
Abandoned
Abandoned Jul 31, 2024
Lipocine, Inc.AbandonedAbandoned Jul 31, 2024
Application 18/437,438Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy
Abandoned
Abandoned Sep 12, 2025
Lipocine Inc.AbandonedAbandoned Sep 12, 2025
9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Lipocine Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited